Evidence map›Paper›PMID 41615538›Full record

ReviewMolecular biology reports2026

Structures, characteristics, and anticancer mechanisms of taxanes, beta-glucans, and isothiocyanates.

Piotr Gromek, Weronika Kruczkowska, Kacper Górecki, Julia Gałęziewska, Elżbieta Płuciennik, Łukasz Janczewski, Mateusz Kciuk, Lin-Yong Zhao, Zbigniew Pasieka, Żaneta Kałuzińska-Kołat and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Piotr GromekDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland.ORCID http://orcid.org/0009-0005-8093-8481
Weronika KruczkowskaDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland.ORCID http://orcid.org/0000-0003-1699-8912
Kacper GóreckiFaculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, Lodz, 90-924, Poland.ORCID http://orcid.org/0009-0005-9796-3886
Julia GałęziewskaDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland.ORCID http://orcid.org/0009-0005-3377-4162
Elżbieta PłuciennikDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland.ORCID http://orcid.org/0000-0002-6682-0402
Łukasz JanczewskiFaculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, Lodz, 90-924, Poland.ORCID http://orcid.org/0000-0003-4689-1622
Mateusz KciukDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, Lodz, 90-237, Poland.ORCID http://orcid.org/0000-0002-8616-3825
Lin-Yong ZhaoDepartment of General Surgery & Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0003-0884-4657
Zbigniew PasiekaDepartment of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, Lodz, 90-136, Poland.ORCID http://orcid.org/0000-0001-8931-0213
Żaneta Kałuzińska-KołatDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland.ORCID http://orcid.org/0000-0002-2335-3293
Damian KołatDepartment of Functional Genomics, Medical University of Lodz, Zeligowskiego 7/9, Lodz, 90-752, Poland. damian.kolat@umed.lodz.pl.ORCID http://orcid.org/0000-0002-1086-3796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The utilization of natural compounds in anticancer treatment has garnered significant attention owing to their promising therapeutic potential and minimal adverse effects compared to conventional methods. The present paper reviews three prominent groups of natural compounds: taxanes, beta-glucans, and isothiocyanates. These three groups were selected based on their clinical evidence, complementary treatment, and recent breakthroughs in delivery systems that warrant a comprehensive review of their structural attributes, biochemical characteristics, and intricate mechanisms of action in cancer. Taxanes stabilize microtubules, disrupt mitotic spindle function, and induce cancer cell apoptosis. Beta-glucans boost immune responses and inhibit cancer cell growth. Isothiocyanates modulate detoxification enzymes, inhibit carcinogens, and induce apoptosis in cancer cells. These groups of natural compounds offer promising anticancer effects and have potential as standalone or adjuvant therapies. We highlight emerging synergistic combinations among these compounds and identify crucial knowledge gaps, particularly in understanding their interactions with the tumor microenvironment and potential applications in immunotherapy-based treatment strategies. Exploring novel delivery strategies and combinatorial approaches could enhance their efficacy while minimizing adverse effects, thereby paving the way for personalized and holistic cancer treatment.

Indexed as

Antineoplastic Agentsbeta-GlucansIsothiocyanatesNeoplasmsTaxoidsAnimalsApoptosisHumansTumor MicroenvironmentAntineoplastic Agentsbeta-GlucansIsothiocyanatesTaxoidsAnticancer treatmentBeta-glucansCancerIsothiocyanatesTaxanes

Identifiers

PMID41615538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.